Global Oncology Drugs Market Size, Status and Forecast 2021-2027

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.

Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.

Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
The industry's leading producers include Roche, Celgene and Novartis, which together account for 35.56% of their 2019 revenues. By region, North America had the highest share of income in 2019, at 43.61%.

Market Analysis and Insights: Global Oncology Drugs Market
The global Oncology Drugs market size is projected to reach US$ 354330 million by 2027, from US$ 178590 million in 2020, at a CAGR of 10.3% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oncology Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oncology Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oncology Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oncology Drugs market.

Global Oncology Drugs Scope and Market Size
Oncology Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oncology Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
According to the type, the income of chemotherapy is the highest, reaching 51.31% in 2019.

Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others
According to the application, blood cancer has the highest share of revenue, more than 22 percent in 2019.

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences